# Q3 2022 webcast

Bieles 1

CEO Pär Fors CFO Pernille Fabricius

November 2, 2022

## Agenda


- Q3 highlights
- Strategic update
- Business Unit performance
- Group financials
- 2022 outlook
- Q&A


#### Disclaimer

This presentation contains forward-looking statements including projections on future financial results. Statements regarding the future are subject to risks and uncertainties that may result in considerable deviations from the outlook. Furthermore, some of these expectations are based on assumptions regarding future events, which may prove incorrect. Please refer to the risk management section on page 47-49 of the Annual Report 2021.

# Q3 highlights

- Continued execution on carveout of infrastructure business
- Global delivery capabilities being consolidated in the Philippines
- Improved earnings and revenue in LSS and CDS drove progress
- Solid order intake including multiyear contract with Lantmännen Unibake





## Strategic update

#### TRANSFORMATION

Specialized IT services provider with two strongly positioned business units

#### **PROFITABILITY**

Continued pickup in Q3 after adjustments and improved utilization

#### **STRATEGY**

SBTi commitment in Q3 Carsten Ringius joins as CFO Pernille Fabricius drives transformation

### **NEXT STEPS**

Carveout work continues Impact being assessed Subject to approvals


#### BACKLOG

Growth based on large new contracts and renewals

NNIT


## Life Sciences Solutions (LSS)

- 20% revenue growth driven by acquisitions and international sales
- Good pickup in earnings due to improved capacity utilization
- Positive development expected to continue on coming quarters
- Solid increase in order intake and backlog from Q3 2021




## Cloud & Digital Solutions (CDS)

- Moderate revenue growth driven by sales to Life Sciences customers
- Stable sales to other customer groups
- Significant profitability increase due to capacity adjustments in Q2
- Continued progress in order backlog with good traction in China and Denmark



## Hybrid Cloud Solutions (HCS)


- Slight decline in revenue caused mainly by SLA contract expiry in Q1
- Increasing electricity costs and higher staff costs during relocation of outsourcing to the Philippines
- Measures taken to increase capacity utilization and cut costs





# **Group financials Q3 and 9M 2022**

DKKm	Q3-22	Q3-21	9M-22	9M-21	FY-21	
Revenue	738	698	2,162	2,139	2,877	•
Revenue growth	5.7%	6.1%	1.1%	1.3%	1.7%	
Gross profit	100	90	232	315	420	۰
Sales and marketing costs	35	36	113	109	145	
Administrative expenses	35	33	109	101	133	
Operating profit before special items	30	21	10	105	142	
Operating margin before special items	4.1%	3.0%	0.5%	4.9%	4.9%	
Special items	50	23	121	92	153	
Operating profit/loss	-20	-2	-111	13	-11	
Net financials	-7	-2	-12	-17	-14	
Net profit/loss	-22	-10	-102	-9	-7	
Free cash flow	-43	-145	-299	-81	11	



# 2022 outlook suspended

- IO business to be reclassified as 'discontinued activities'
- Impact on financial reporting still pending
- Temporary suspension maintained
- Strengthen revenue and profitability of continuing activities from 2023



# **Closing remarks**



Growth in revenue, earnings and backlog in LSS and CDS

Impact of divestment on continuing business still pending














# **Contact information**

Pernille Fabricius CFO <u>PNFA@nnit.com</u>



NNIT

# We make a mark

# **Appendix: Life Sciences Solutions**

DKKm	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Revenue	229	222	198	199	191
Life Sciences (excl. NGG)	208	201	170	175	166
- Life Sciences (Int.)	202	192	163	167	160
- Life Sciences (DK)	6	9	7	8	6
Novo Nordisk Group	21	21	28	24	24
Public	0	0	0	0	1
Production costs	180	180	170	150	145
Gross profit	49	42	28	49	46
Gross profit margin	21.4%	18.9%	14.6%	24.6%	24.1%
Order backlog	752	674	541	408	684

# **Appendix: Cloud & Digital Solutions**

DKKm	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2022
Revenue	207	206	213	225	199
Life Sciences (excl. NGG)	42	35	35	40	31
- Life Sciences (Int.)	18	12	11	17	12
- Life Sciences (DK)	24	23	24	23	19
Novo Nordisk Group	25	23	23	23	21
Enterprise	100	103	106	111	101
Public	34	37	40	41	38
Finance	6	8	9	10	8
Production costs	165	189	186	184	174
Gross profit	42	17	27	41	25
Gross profit margin	20.3%	8.3%	12.7%	18.2%	12.6%
Order backlog	816	756	656	597	822

# **Appendix: Hybrid Cloud Solutions**

DKKm	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2022
Revenue	302	295	290	314	308
Life Sciences (excl. NGG)	36	37	39	45	48
- Life Sciences (Int.)	14	10	14	15	15
- Life Sciences (DK)	22	27	25	30	33
Novo Nordisk Group	97	90	89	107	98
Enterprise	81	86	81	83	81
Public	25	22	24	25	25
Finance	63	60	57	54	56
Production costs	293	288	280	299	290
Gross profit	9	7	10	15	18
Gross profit margin	3.0%	2.4%	3.4%	4.8%	5.8%
Order backlog	1,191	1,142	997	1,012	1,284